Athira Pharma (NASDAQ:ATHA) Stock Price Up 9.1% – What’s Next?

Athira Pharma, Inc. (NASDAQ:ATHA) shot up 9.1% on Tuesday . The company traded as high as $4.49 and last traded at $4.21. 285,271 shares traded hands during mid-day trading, an increase of 1,127% from the average session volume of 23,243 shares. The stock had previously closed at $3.86.

Analysts Set New Price Targets

Separately, Mizuho set a $4.00 target price on Athira Pharma in a research note on Friday.

Athira Pharma Stock Up 9.1%

The stock has a market cap of $16.59 million, a PE ratio of -0.27 and a beta of 3.01. The firm has a 50-day simple moving average of $3.96 and a 200-day simple moving average of $3.32.

Athira Pharma (NASDAQ:ATHA) last posted its earnings results on Thursday, August 7th. The company reported ($1.80) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($1.80). On average, research analysts expect that Athira Pharma, Inc. will post -2.35 earnings per share for the current year.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Athira Pharma stock. BML Capital Management LLC lifted its position in Athira Pharma, Inc. (NASDAQ:ATHA) by 15.3% during the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 3,200,667 shares of the company’s stock after purchasing an additional 424,782 shares during the quarter. Athira Pharma comprises approximately 0.7% of BML Capital Management LLC’s portfolio, making the stock its 19th largest holding. BML Capital Management LLC owned approximately 8.20% of Athira Pharma worth $912,000 at the end of the most recent quarter. Institutional investors and hedge funds own 57.12% of the company’s stock.

Athira Pharma Company Profile

Athira Pharma, Inc, a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its lead product candidate is Fosgonimeton (ATH-1017), a small molecule designed to modulate the neurotrophic hepatocyte growth factor (HGF) system and its receptor, MET, for a healthy nervous system that is in LIFT-AD Phase 2/3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease dementia and Dementia with Lewy bodies.